skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; « less
Publication Date:
Research Org.:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE Office of Science (SC)
OSTI Identifier:
1438922
Resource Type:
Journal Article
Journal Name:
Cancer Research
Additional Journal Information:
Journal Volume: 74; Journal Issue: 20; Journal ID: ISSN 0008-5472
Publisher:
American Association for Cancer Research
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barriere, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., Hoffman-Luca, C. G., Lu, J., Shangary, S., Yu, S., Bernard, D., Aguilar, A., Dos-Santos, O., Besret, L., Guerif, S., Pannier, P., Gorge-Bernat, D., and Debussche, L. SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression. United States: N. p., 2014. Web. doi:10.1158/0008-5472.CAN-14-0799.
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barriere, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., Hoffman-Luca, C. G., Lu, J., Shangary, S., Yu, S., Bernard, D., Aguilar, A., Dos-Santos, O., Besret, L., Guerif, S., Pannier, P., Gorge-Bernat, D., & Debussche, L. SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression. United States. https://doi.org/10.1158/0008-5472.CAN-14-0799
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barriere, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., Hoffman-Luca, C. G., Lu, J., Shangary, S., Yu, S., Bernard, D., Aguilar, A., Dos-Santos, O., Besret, L., Guerif, S., Pannier, P., Gorge-Bernat, D., and Debussche, L. 2014. "SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression". United States. https://doi.org/10.1158/0008-5472.CAN-14-0799.
@article{osti_1438922,
title = {SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression},
author = {Wang, S. and Sun, W. and Zhao, Y. and McEachern, D. and Meaux, I. and Barriere, C. and Stuckey, J. A. and Meagher, J. L. and Bai, L. and Liu, L. and Hoffman-Luca, C. G. and Lu, J. and Shangary, S. and Yu, S. and Bernard, D. and Aguilar, A. and Dos-Santos, O. and Besret, L. and Guerif, S. and Pannier, P. and Gorge-Bernat, D. and Debussche, L.},
abstractNote = {},
doi = {10.1158/0008-5472.CAN-14-0799},
url = {https://www.osti.gov/biblio/1438922}, journal = {Cancer Research},
issn = {0008-5472},
number = 20,
volume = 74,
place = {United States},
year = {Thu Aug 21 00:00:00 EDT 2014},
month = {Thu Aug 21 00:00:00 EDT 2014}
}

Works referenced in this record:

p53 and Human Cancer: The First Ten Thousand Mutations
book, January 1999


The p53-mdm-2 autoregulatory feedback loop.
journal, July 1993


Functions of the MDM2 oncoprotein
journal, January 1999


MDM2 — master regulator of the p53 tumor suppressor protein
journal, January 2000


MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
journal, February 2005


The MDM2 gene amplification database
journal, August 1998


Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
journal, March 2008


p53 Activation by Small Molecules:  Application in Oncology
journal, July 2005


MDM2 inhibitors for cancer therapy
journal, January 2007


Targeting the MDM2-p53 Interaction for Cancer Therapy
journal, September 2008


Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics
book, January 2012


Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinic
journal, May 2013


A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
journal, June 2013


Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold
journal, May 2012


Label-Free Detection of Biomolecular Interactions Using BioLayer Interferometry for Kinetic Characterization
journal, September 2009


Phaser crystallographic software
journal, July 2007


Coot model-building tools for molecular graphics
journal, November 2004


Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
journal, June 2007


An inhibitor of Bcl-2 family proteins induces regression of solid tumours
journal, May 2005


Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
journal, December 2012


Crystal Structure of a β-Catenin/BCL9/Tcf4 Complex
journal, October 2006


Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
journal, November 1996


Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
journal, January 2006


How the Bcl-2 family of proteins interact to regulate apoptosis
journal, February 2006


Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
journal, January 1995


Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways
journal, October 2006


Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction
journal, May 2012


Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
journal, May 2013


Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
journal, December 2006


Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
journal, January 2007


Restoration of p53 function leads to tumour regression in vivo
journal, January 2007


Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms
journal, August 2008


Works referencing / citing this record:

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
journal, October 2018


Synthesis and cytotoxicity of novel dispiro derivatives of 5-arylidenoxazolones, potential inhibitors of p53—MDM2 protein-protein interaction
journal, March 2018


How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures
journal, December 2015


Early and multiple origins of metastatic lineages within primary tumors
journal, February 2016


The chemistry and pharmacology of privileged pyrroloquinazolines
journal, January 2015


MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
journal, July 2017


Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
journal, October 2016


Therapeutic targeting of tumor suppressor genes: Therapeutic Targeting of Tumors
journal, December 2014


RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
journal, November 2019


Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
journal, January 2018


Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations
journal, April 2019


The Role of MDM2 in Promoting Genome Stability versus Instability
journal, October 2017


The utilization of spirocyclic scaffolds in novel drug discovery
journal, June 2016


Chemical Variations on the p53 Reactivation Theme
journal, May 2016


Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors
journal, March 2017


RSK3: A regulator of pathological cardiac remodeling: Regulation and Function of RSK3 in Cardiac Remodeling
journal, May 2015


2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008–2014)
journal, December 2015


A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation
journal, January 2019


Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
journal, December 2016


Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
journal, July 2018


MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
journal, July 2017


The role of p53 in cancer drug resistance and targeted chemotherapy
journal, November 2016


A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53 wt osteosarcoma cells
journal, February 2019


Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
journal, December 2017


Targeting MDM2 for novel molecular therapy: Beyond oncology
journal, October 2019


Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction: STRATEGIES TO DISRUPT THE p53-MDM2/MDMX INTERACTION
journal, June 2016


Synthesis of benzosuberone-tethered spirooxindoles: 1-3-dipolar cycloaddition of azomethine ylides and arylidene benzosuberones
journal, December 2018


Efficient synthesis of tetrahydronaphthalene- or isochroman-fused spirooxindoles using tandem reactions
journal, January 2015


Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
journal, February 2015


Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
journal, August 2018


Chiral bifunctional bisphosphine enabled enantioselective tandem Michael addition of tryptamine-derived oxindoles to ynones
journal, January 2019


A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
journal, March 2019


Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
journal, October 2018


Design, synthesis and evaluations of spiro‐fused benzoxaborin derivatives as novel boron‐containing compounds
journal, March 2019


Targeting Transcription Factors for Cancer Treatment
journal, June 2018


Organocatalytic asymmetric Michael addition between 3-subsituted oxindoles and enals catalyzed by camphor sulfonyl hydrazine
journal, January 2019


Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments
journal, May 2019


Targeting transcription factors in acute myeloid leukemia
journal, June 2018


The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53
journal, October 2019


Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
journal, April 2016


Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
journal, March 2017


Cellular Senescence: Aging, Cancer, and Injury
journal, April 2019


P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
journal, March 2016